CELL-MEDIATED IMMUNITY IN CYTOMEGALOVIRUS INFECTIONS

Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

CELL-MEDIATED IMMUNITY IN CYTOMEGALOVIRUS INFECTIONS

Herpesviruses; 4:121-45 1985. Unique Identifier : AIDSLINE ICDB/85615640
Quinnan GV Jr; Natl. Center for Drugs and Biologics, Div. of Virology, Office of; Biologics, Food and Drug Administration, Bethesda, MD 20205

Abstract: The many interactions between cytomegalovirus (CMV) and host cellular immunity include some of the most clinically significant, complex, and fascinating problems in viral immunology. Most clinically important diseases caused by CMV occur in individuals with deficient cellular immunity. Cell-mediated immunity in CMV infections is discussed under the following headings: characteristics of effector cell functions relevant in CMV infections (natural killer (NK) cells and other large granular lymphocytes; antibody-dependent cell-mediated cytotoxicity; cytotoxic T cells), virus-specific cytotoxic lymphocyte responses during CMV infections, evidence that virus-specific cytotoxic lymphocytes determine the outcome of CMV infections, evidence that NK cells and other large granular lymphocytes are important in CMV infections, causes of depressed cytotoxic T-cell responses and NK cell activity in high-risk populations, delayed-type hypersensitivity responses to CMV, CMV-induced immune suppression, CMV-induced in vitro lymphocyte blastogenesis, and cellular immune responses to CMV vaccine. The importance of CMV as a cause of human disease in many different settings is related more to the overriding significance of cell-mediated immunity than to the inherent virulence of the agent itself. As a result of many recent advances in the general field of cellular immunology, it is now possible to define the effector cell functions that are important for defense of the host and to understand why they fail to develop in some individuals. (62 Refs)

Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS Animal Antibody-Dependent Cell Cytotoxicity Bone Marrow/TRANSPLANTATION Bone Marrow Transplantation Cytomegalovirus/IMMUNOLOGY Cytomegalovirus Infections/COMPLICATIONS/*IMMUNOLOGY Cytotoxicity, Immunologic Human Hypersensitivity, Delayed HLA Antigens/IMMUNOLOGY Immunity, Cellular Kidney/TRANSPLANTATION Kidney Transplantation Killer Cells, Natural/IMMUNOLOGY Mice T-Lymphocytes, Cytotoxic/IMMUNOLOGY T-Lymphocytes, Suppressor-Effector/IMMUNOLOGY Transplantation Immunology Viral Vaccines/IMMUNOLOGY JOURNAL ARTICLE REVIEW

860130
M8610181

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .